Plural Ring Nitrogens In The Bicyclo Ring System Patents (Class 514/234.5)
-
Patent number: 10508118Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.Type: GrantFiled: April 25, 2016Date of Patent: December 17, 2019Assignee: Xiamen UniversityInventors: Xianming Deng, Zhongji Zhuang, Zhou Deng, Xiaoxing Huang, Yan Liu, Ting Zhang, Wei Huang, Qingyan Xu, Zhiyu Hu
-
Patent number: 10507210Abstract: Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents.Type: GrantFiled: December 3, 2015Date of Patent: December 17, 2019Assignee: Auckland UniServices LimitedInventors: Adam Vorn Patterson, Jeffrey Bruce Smaill, Shevan Silva, Christopher Paul Guise, Matthew Roy Bull, Victoria Jackson, Tillman Pearce, Nipun Davar
-
Patent number: 10494360Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: GrantFiled: March 8, 2017Date of Patent: December 3, 2019Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.VInventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Patent number: 10472353Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: April 19, 2019Date of Patent: November 12, 2019Assignee: University Health NetworkInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Composition comprising diacid derivatives and their use in the treatment of collagenic eye disorders
Patent number: 10463610Abstract: The present invention relates to novel pharmaceutical formulations. More specifically, the present invention relates to novel pharmaceutical formulations that are suitable for intraocular administration. The present invention also relates to the use of these formulations for the treatment of collagenic eye disorder such as, for example, the treatment of keratoconus.Type: GrantFiled: November 3, 2016Date of Patent: November 5, 2019Assignee: The University of LiverpoolInventors: Rachel L. Williams, Colin E. Willoughby -
Patent number: 10456407Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.Type: GrantFiled: April 20, 2016Date of Patent: October 29, 2019Assignees: Epizyme, Inc., Health Research, Inc.Inventors: Heike Keilhack, Roberto Pili
-
Patent number: 10450300Abstract: Inhibitors of Wnt signaling pathway with structures of Formula I are disclosed, together with their pharmaceutical salts. Applications of compounds of Formula I in inhibiting or modulating the Wnt signaling pathway are also disclosed. Compounds of Formula I can treat disorders caused by aberrant activation of the Wnt signaling pathway.Type: GrantFiled: October 6, 2016Date of Patent: October 22, 2019Assignee: Suzhou Yunxuan Yiyao Keji Youxian GongsiInventor: Xiaohu Zhang
-
Patent number: 10435391Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.Type: GrantFiled: April 20, 2016Date of Patent: October 8, 2019Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
-
Patent number: 10413540Abstract: Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.Type: GrantFiled: March 30, 2018Date of Patent: September 17, 2019Assignee: Corcept Therapeutics, Inc.Inventor: Hazel Hunt
-
Patent number: 10398693Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.Type: GrantFiled: July 18, 2018Date of Patent: September 3, 2019Assignee: IGNYTA, INC.Inventors: Daniel Codallos, Jr., Robert Orr, Ching-Yuan Li, Valerie Denise Start
-
Patent number: 10392374Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: February 1, 2018Date of Patent: August 27, 2019Assignee: University Health NetworkInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Patent number: 10370380Abstract: The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.Type: GrantFiled: November 23, 2016Date of Patent: August 6, 2019Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Chuanfei Jin, Ji Zhang
-
Patent number: 10370328Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.Type: GrantFiled: April 28, 2016Date of Patent: August 6, 2019Assignee: MUSC Foundation for Research DevelopmentInventors: Craig C. Beeson, Christopher C. Lindsey, Baerbel Rohrer, Yuri Karl Peterson
-
Patent number: 10350202Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.Type: GrantFiled: November 15, 2017Date of Patent: July 16, 2019Assignee: 442 Ventures, LLCInventor: J. Mark Jackson
-
Patent number: 10351532Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: GrantFiled: December 29, 2015Date of Patent: July 16, 2019Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Patent number: 10336748Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.Type: GrantFiled: January 29, 2016Date of Patent: July 2, 2019Assignee: Pfizer Inc.Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
-
Patent number: 10308631Abstract: A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.Type: GrantFiled: June 10, 2016Date of Patent: June 4, 2019Assignee: NATIONAL UNIVERSITY OF SINGAPOREInventors: Sang Hyun Lee, Brian William Dymock, Mayumi Kitagawa, Cheng Shang See
-
Patent number: 10278976Abstract: The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject.Type: GrantFiled: December 11, 2015Date of Patent: May 7, 2019Assignee: Mira Dx, Inc.Inventor: Joanne Weidhaas
-
Patent number: 10265320Abstract: Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: GrantFiled: May 25, 2016Date of Patent: April 23, 2019Assignees: The Research Foundation for The State University of New York, New York UniversirtyInventors: Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
-
Patent number: 10266529Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.Type: GrantFiled: August 25, 2017Date of Patent: April 23, 2019Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
-
Patent number: 10213445Abstract: The present disclosure provides methods utilizing the diazeniumdiolate-based prodrugs for the treatment of cancer via various mechanisms and procedures. The disclosure also provides kits comprising the diazeniumdiolate-based prodrugs.Type: GrantFiled: November 6, 2015Date of Patent: February 26, 2019Assignees: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate, The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Katrina M. Miranda, David A. Wink, Debashree Basudhar
-
Patent number: 10206924Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.Type: GrantFiled: December 15, 2015Date of Patent: February 19, 2019Assignee: The Regents of the University of MichiganInventors: Christopher Emil Whitehead, Judith S. Leopold
-
Patent number: 10202330Abstract: The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A?), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy.Type: GrantFiled: September 2, 2015Date of Patent: February 12, 2019Assignee: ORYZON GENOMICS, SAInventors: Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe
-
Patent number: 10150783Abstract: Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.Type: GrantFiled: May 31, 2017Date of Patent: December 11, 2018Assignee: ACLARIS THERAPEUTICS, INC.Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman
-
Patent number: 10105324Abstract: Disclosed is a method of treating or ameliorating a condition which can be treated or ameliorated by the administration of guaifenesin, which method comprises orally administering to a subject in need thereof an effective amount of an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.Type: GrantFiled: October 30, 2017Date of Patent: October 23, 2018Assignee: SOVEREIGN PHARMACEUTICALS, LLCInventor: Paul Hafey
-
Patent number: 10100058Abstract: The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.Type: GrantFiled: November 29, 2017Date of Patent: October 16, 2018Assignee: Gilead Sciences, Inc.Inventors: Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry, Scott Preston Simonovich, Jeff Zablocki, Christopher Allen Ziebenhaus
-
Patent number: 10093657Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.Type: GrantFiled: March 9, 2017Date of Patent: October 9, 2018Assignees: HOFFMANN-LA ROCHE INC., CHUGAI PHARMACEUTICAL CO.Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
-
Patent number: 10071091Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: May 8, 2017Date of Patent: September 11, 2018Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
-
Patent number: 10064834Abstract: The present invention includes a method of inhibiting or reducing mTOR signaling or inhibition of indoleamine dioxygenase-1 (IDO1) in a subject with a proliferative disease, which comprises administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: May 9, 2017Date of Patent: September 4, 2018Assignee: Texas Tech University SystemInventors: Vadivel Ganapathy, Yangzom D. Bhutia, Babu Ellappan, Sabarish Ramachandran
-
Patent number: 10053737Abstract: The invention is directed to methods, reagents, and kits for the detection of MAPK/ERK pathway mutations in a patient diagnosed for cancer. In one embodiment, the invention comprises a sensitive and selective method to identify mutations to the BRAF, KRAS, and NRAS genes in a single reaction. In another aspect of this embodiment, the invention comprises primers and probes for the detection of the BRAF, KRAS, and NRAS mutations using a single nucleotide primer extension assay. In another embodiment the invention is used to identify and select patients amenable for treatment with an ERK inhibitor.Type: GrantFiled: April 3, 2014Date of Patent: August 21, 2018Assignee: MERCK SHARP & DOHME CORP.Inventors: Ken C. N. Chang, Stefan Galuska, Matthew J. Marton
-
Patent number: 10052284Abstract: The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 6, 2017Date of Patent: August 21, 2018Assignee: TRANSLATE BIO, INC.Inventors: Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
-
Patent number: 10045962Abstract: Provided in the present invention are uses of duloxetine hydrochloride in preparing a pharmaceutical composition for treatment of cancer.Type: GrantFiled: April 20, 2017Date of Patent: August 14, 2018Assignee: LAUNX BIOMEDICAL CO., LTD.Inventors: Chiu-Hung Chen, Show-Mei Chuang, Tzong-Der Way, Nai-Wan Hsiao
-
Patent number: 10035777Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.Type: GrantFiled: July 27, 2015Date of Patent: July 31, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Bireshwar Dasgupta, Susheel Jethanand Nara, Vivekananda M. Vrudhula, Senliang Pan, Richard A. Hartz, Ramkumar Rajamani
-
Patent number: 10022387Abstract: The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.Type: GrantFiled: January 25, 2017Date of Patent: July 17, 2018Assignee: Incyte CorporationInventors: Ge Zou, Andrew P. Combs, Andrew W. Buesking
-
Patent number: 10023569Abstract: A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (X): or a pharmaceutically acceptable salt thereof with Compound (Y): in the presence of a palladium catalyst and a carbonate or phosphate base to form compound (Z): or a pharmaceutically acceptable salt thereof; and (b) deprotecting the Ts group of Compound (Z) to form Compound (1) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 10, 2016Date of Patent: July 17, 2018Assignee: Vertex Pharmaceuticals IncorporatedInventors: Gerald J. Tanoury, William Aloysius Nugent, Vadims Dvornikovs, Peter Jamison Rose
-
Patent number: 10016390Abstract: Provided in the present invention are uses of duloxetine hydrochloride in preparing a pharmaceutical composition for treatment of cancer.Type: GrantFiled: April 20, 2017Date of Patent: July 10, 2018Assignee: LAUNX BIOMEDICAL CO., LTD.Inventors: Chiu-Hung Chen, Show-Mei Chuang, Tzong-Der Way, Nai-Wan Hsiao
-
Patent number: 9994529Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.Type: GrantFiled: February 14, 2017Date of Patent: June 12, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Michael Jonathan Bury, Linda N. Casillas, Adam K. Charnley, Michael P. Demartino, Xiaoyang Dong, Patrick M. Eidam, Pamela A. Haile, Robert W. Marquis, Jr., Joshi M. Ramanjulu, Joseph J. Romano, Ami Lakdawala Shah, Robert R. Singhaus, Jr., Gren Wang
-
Patent number: 9962348Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.Type: GrantFiled: July 14, 2017Date of Patent: May 8, 2018Assignee: The Rockefeller UniversityInventors: Sohail F. Tavazoie, Nora Pencheva
-
Patent number: 9949932Abstract: Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition.Type: GrantFiled: June 9, 2016Date of Patent: April 24, 2018Assignee: Gilead Connecticut, Inc.Inventors: Melissa Jean Casteel, Bei Li, Rowchanak Pakdaman, Diana Sperger, Dimitrios Stefanidis
-
Patent number: 9943519Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: June 26, 2014Date of Patent: April 17, 2018Assignees: Genentech, Inc., F. Hoffmann-La Roche AGInventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzer-Toste, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
-
Increasing survival of free tissue grafts and flaps using phosphodiesterase type 5 (PDE5) inhibitors
Patent number: 9943398Abstract: The present invention relates to methods of tissue grafting and microvascular free flap transfer that involve administering a phosphodiesterase type-5 inhibitor to the tissue graft or microvascular free flap to produce a treated graft or flap, and implanting the treated graft or flap into a recipient site of a host subject.Type: GrantFiled: July 16, 2013Date of Patent: April 17, 2018Assignee: New York UniversityInventor: Daniel J. Ceradini -
Patent number: 9884855Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.Type: GrantFiled: October 17, 2014Date of Patent: February 6, 2018Assignee: University Health NetworkInventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
-
Patent number: 9873690Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.Type: GrantFiled: March 17, 2016Date of Patent: January 23, 2018Assignees: Pfizer Inc, iTeos TherapeuticsInventors: Sacha Ninkovic, Stefano Crosignani, Indrawan James McAlpine, Michael Raymond Collins, Stephanie Anne Scales, Andreas Maderna, Martin Wythes
-
Patent number: 9862704Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders.Type: GrantFiled: December 19, 2014Date of Patent: January 9, 2018Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.Inventors: Hervé Geneste, Wilfried Hornberger, Charles W. Hutchins, Katja Jantos, Andreas Kling, Loic Laplanche, Marcel Van Gaalen
-
Patent number: 9796703Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.Type: GrantFiled: February 23, 2017Date of Patent: October 24, 2017Assignee: University Health NetworkInventors: Graham Cumming, Narendra Kumar B. Patel, Bryan T. Forrest, Yong Liu, Sze-Wan Li, Peter Brent Sampson, Louise G. Edwards, Heinz W. Pauls
-
Patent number: 9796709Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and R1 is a hydrogen atom or a hydroxy group.Type: GrantFiled: December 12, 2014Date of Patent: October 24, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Hideki Kobayashi, Masami Arai, Toshio Kaneko, Naoki Terasaka
-
Patent number: 9789117Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms.Type: GrantFiled: May 18, 2012Date of Patent: October 17, 2017Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Jose Miguel Vela Hernandez, Maria Isabel Martin Fontelles
-
Patent number: 9790198Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.Type: GrantFiled: October 8, 2015Date of Patent: October 17, 2017Assignee: Janssen Pharmaceutica NVInventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
-
Patent number: 9771327Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:Type: GrantFiled: March 13, 2014Date of Patent: September 26, 2017Assignee: FLATLEY DISCOVERY LAB, LLCInventors: Michael P. Zawistoski, Yevgen Barsukov, Bridget M. Cole, Richard A. Nugent
-
Patent number: 9763900Abstract: This invention relates to chemistry and biochemistry applied to the field of medicine and is referred to a new method of prevention and therapeutic treatment of conformational diseases (CD), in particular to amyloid origin diseases by administrating an effective amount of one or more compounds, salts, prodrugs or solvates, which are considered herein as chemical chaperonins, of Formula I, Where: R1: -alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O—R4; R3: —COOH, —OH, —SH, —NH2, —NH-alkyl-, —NH-dithiocarbamate-alkyl, —N-alkyl-dithiocarbamate alkaline earth metal salts. R4: succinimidyl group. R2: —H, -alkyl; wherein the term “alkyl” is characterized by a linear or branched aliphatic chain, hydrogen and saturated carbon atoms, comprising a methyl, ethyl, n-propyl, iso-propyl, n-butyl or iso-butyl groups. Wherein, the term “alkylenyl” refers to a divalent analog of a linear or branched alkyl group, preferably ethylenyl (—CH2CH2—) or butylenyl (—CH2CH2CH2CH2—) radicals.Type: GrantFiled: December 30, 2013Date of Patent: September 19, 2017Assignee: CENTRO DE NEUROCIENCIAS DE CUBAInventors: Marquiza Sablón Carrazana, Chryslaine Rodriguez-Tanty, Myriam Marlene Altamirano Bustamante, Fernand Vedrenne Gutiérrez, Suchitil Rivera Marrero, Isaac Fernández Gómez, Rosa María López Barroso, Lina Andrea Rivillas Acevedo, Reyna Lara Martinez, Rafaela Perez Perera, Alberto Bencomo Martínez, María Guadalupe Domínguez Macouzet, Luis Felipe Jiménez García, Massiel Díaz Miranda, Julio Morán Andrade, Pedro Valdés Sosa, Alejandro Perera Pintado, Anaís Prats Capote, Sergio Agustín Islas Andrade